Developing Regenerative Gene Therapies with the Potential to Transform Respiratory Medicine
OmniSpirant Limited was founded by Gerry McCauley in 2016. Gerry qualified as a Master of Pharmacy in 2001. Gerry has extensive commercial knowledge, industry contacts and has built an international network of experts in the fields of cell and gene therapy and respiratory drug delivery.
Gerry is the inventor of OmniSpirant’s patent pending inhaled exosome technology. Ongoing Cystic Fibrosis (CF) research is expected to generate game changing in vitro data by Q2 2020. OS002, our discovery stage COPD program, has the game changing potential to reverse established disease damage and restore lung function. OmniSpirant are currently seeking seed investment to fund further CF and COPD preclinical studies and develop scalable GMP manufacturing of the novel exosome therapeutics. In time, it is hoped that similar breakthrough potential can be unlocked in treating other lung diseases of high unmet patient need - e.g. Lung Adenocarcinoma, Pulmonary Hypertension and IPF.